The efficacy and safety of
clopidogrel compared with
ticagrelor as part of dual antiplatelet
therapy in patients, and in older patients, with
acute coronary syndrome is reviewed. PubMed, Embase, the Cochrane Library, MEDLINE, and HTA databases were searched (September 2, 2020) for randomized controlled trials (RCTs). Pooled risk differences (
clopidogrel minus
ticagrelor) were estimated using random-effects meta-analyses, and certainty of evidence was assessed according to Grading of Recommendations Assessment, Development, and Evaluation. In all, 29 RCTs were identified. The risk difference for all-cause mortality was 0.6% (-0.03% to 1.3%), cardiovascular (CV) mortality: 0.6% (95% confidence interval: 0.01% to 1.1%),
myocardial infarction (MI): 0.9% (0.4% to 1.3%),
stent thrombosis: 0.7% (0.4 to 1.1%), clinically significant
bleeding: -1.9% (-3.7% to -0.2%), major
bleeding: -0.9% (-1.6% to -0.1%), and
dyspnea: -5.8% (-7.7% to -3.8%). In older patients, there were no differences between the comparison groups regarding all-cause mortality, CV mortality, and MI, whereas the risk of clinically significant
bleeding and major
bleeding was lower in the
clopidogrel group, -5.9% (-11 to -0.9%, 1 RCT) and -2.4% (-4.4% to -0.3%), respectively. Compared with
ticagrelor,
clopidogrel may result in little or no difference regarding all-cause mortality. Although not evident in older patients, it cannot be excluded that
clopidogrel may be slightly less efficient in reducing the risk of CV mortality and MI, whereas
ticagrelor is probably more efficacious in reducing the risk of
stent thrombosis.
Clopidogrel results in a reduced risk of
dyspnea and clinically significant
bleeding and in older people probably in a reduced risk of major
bleeding.